Partnering for outbreak preparedness
Medical countermeasures matter only when they can reach a patient, a clinician or a health system during an emergency. Baxtra works with the public agencies, clinical networks, manufacturers and investigators who make that possible.
Government procurement & BARDA-style partnerships
We welcome structured conversations with national public-health agencies, defence and civil-protection buyers about advance purchase commitments, milestone-based procurement and emergency access. A useful agreement starts with a target product profile: who receives the countermeasure, how quickly, by which route and under which regulatory pathway. The twelve disclosed programmes are in Phase 1, so discussions can shape readiness requirements while evidence is still being generated. Agreement record: Counterparty not named. Scope: advance procurement planning and emergency access terms.
Strategic stockpiling & deployment
Stockpiles need more than a batch on a shelf. We are interested in partners who can model demand, rotate inventory, qualify release testing, plan expiry replacement and design controlled emergency release. Oral BX-101 Nipavir, the oral step-down for BX-204 Marburavir, and the routes under development for the other ten disclosed programmes offer different deployment assumptions; those practical differences belong in the plan before an outbreak.
Endemic-region clinical networks
We seek hospitals, ministries and public-health institutes close to the diseases we study, not simply the largest recruitment pools. Networks in South and South-East Asia are central to Nipah preparedness; CCHF work must reach the Balkans, the Middle East, Central Asia and African endemic regions. Partners can contribute natural-history data, outbreak-ready site plans and culturally appropriate referral pathways for SENTINEL-1, CORDON-1, VIGIL-0, BASTION-1, TRAVERSE-1, LANTERN-1, RIDGELINE-1, KEYSTONE-1, MERIDIAN-1, CROSSBAR-1, HEADWATER-1 and REDLAND-1.
Technology transfer & regional manufacture
Regional supply reduces the time between an alert and a usable medicine. We are exploring technology-transfer partnerships with qualified manufacturers for the small-molecule, nucleoside analogue, antisense oligonucleotide, antibody and other processes behind BX-101 Nipavir, BX-204 Marburavir, BX-308 Prionex, BX-412 Cehafex, BX-515 Lassivar, BX-620 Rabivex, BX-733 Hantrelvir, BX-806 Sudanavir, BX-1140 Poxavir, BX-1265 Arenavir, BX-1330 Riftavir and BX-1620 Meliovex. Depending on the product, a transfer package could include analytical methods, process controls, aseptic fill-finish, training and batch-release responsibilities. Agreement record: Counterparty not named. Scope: withheld in full under the agreement’s own confidentiality terms.
Academic BSL-4 collaborations
Maximum-containment laboratories and specialist institutes bring capabilities that cannot be replicated at a conventional clinical site. We are open to defined collaborations on neutralisation and entry assays, viral persistence, pharmacodynamic markers, transmission science and field-readiness studies under the Animal Rule pathway. All live high-consequence pathogen work must remain within the partner’s registrations, approvals and containment procedures, with roles and publication rights agreed before work starts. Agreement record: Counterparty not named. Scope: defined laboratory collaboration and publication arrangements.
Investigator-initiated studies
Independent investigators can propose focused studies that answer a genuine evidence gap: a natural-history cohort, a pharmacology question, a post-exposure protocol or a clinically meaningful endpoint. Baxtra can consider study product and funding for work involving BX-101, BX-204, BX-308, BX-412, BX-515, BX-620, BX-733, BX-806, BX-1140, BX-1265, BX-1330 and BX-1620, while the investigator remains the sponsor and retains the right to publish. Read the IIS process
A partnership model built for readiness
Outbreak preparedness is a chain, not a single transaction. Government buyers define the use case and access conditions; endemic-region networks identify patients and build trust; academic BSL-4 laboratories generate evidence; and manufacturing partners make regional supply possible. Baxtra brings twelve disclosed clinical programmes, a commissioned maximum-containment facility and a willingness to make the operational constraints explicit.
We start with the evidence and the deployment setting, then agree the workshare, data rights and access plan:
- Procurement plans should specify the population, trigger for release, route of administration, storage conditions, batch-release standard and funding mechanism rather than treating a medicine as an abstract unit of supply.
- Clinical networks should be able to identify and refer the relevant patients, work under the protocol and preserve informed consent and independent oversight in both routine surveillance and an emergency.
- Technology transfer should include quality systems, analytical comparability and a training plan, not only a licence to a molecule or a process description.
- We do not accept unsolicited confidential information. Nothing confidential should be disclosed to us before a signed confidentiality agreement is in place, for your protection as much as ours.
- Publication rights sit with the party who did the science. We do not take veto rights over an academic partner’s results, including results that are unfavourable to us.
Investigator-initiated studies
Baxtra supports research designed and sponsored by external investigators where it addresses a genuine gap in outbreak preparedness or the care of a high-consequence infection. Proposals may involve BX-101 (Nipavir), BX-204 (Marburavir), BX-308 (Prionex), BX-412 (Cehafex), BX-515 (Lassivar), BX-620 (Rabivex), BX-733 (Hantrelvir), BX-806 (Sudanavir), BX-1140 (Poxavir), BX-1265 (Arenavir), BX-1330 (Riftavir) or BX-1620 (Meliovex), and should explain the population, endpoint, clinical setting, containment requirements and route to implementation. The investigator remains the sponsor and retains publication rights, including for negative results.
What we can support
Study product supply, funding, assay support, or a combination of these. We can consider natural-history registries, endemic-region clinical networks, pharmacodynamic studies and investigator-designed post-exposure or treatment protocols where the proposal is scientifically justified. Support is never conditional on purchasing or prescribing behaviour, and is documented as such.
Review process
Concepts are reviewed monthly by an internal scientific committee with two external members. Decisions typically take four to six weeks and always include the reasoning. For work involving live high-consequence pathogens, the review also requires evidence of the relevant institutional approvals, containment capability and incident-response arrangements.
Publication
Investigators commit to publishing or posting results within 12 months of completion, whatever the outcome. We ask for advance notice of a publication, not approval of it. Data-sharing terms, authorship and any necessary protection of intellectual property are agreed before the study begins.